Managed Healthcare Executive October 10, 2024
Formulary Watch

The IQVIA analysis finds that the impact of drug price negotiation on patients’ out-of-pocket spending could also be smaller than expected.

The impact of the Inflation Reduction Act’s drug price negotiations is likely to be more complex, and patients may not see the expected higher out-of-pocket savings, according to a new analysis from IQVIA Institute for Human Data Science that was commissioned by We Work For Health, a life-sciences focused policy organization.

Price negotiations are unlikely to lead to additional savings for patients because the 10 drugs chosen by the Centers for Medicare and Medicaid Services are already subject to aggressive negotiations and significant rebates, the report finds.

IQVIA suggests the out-of-pocket savings for beneficiaries from the IRA’s $2,000 cap...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Insurance, Medicare, Patient / Consumer, Survey / Study, Trends
How to beat the 5 devils of modern medicine and live a longer, happier life
Personalization key to patient satisfaction with AI doctors
Digital twins could provide more tailored health care in the future
How to engage parents in autism therapy [PODCAST]
Dengue fever cases more than double 2024 total: 4 notes

Share This Article